About us

The Barricaid implant breakthrough all started with inventor Greg Lambrecht, whose firsthand experience with his mother’s recurrent disc herniations inspired him to search for a better solution.

For two decades, Intrinsic Therapeutics has worked with world-renowned surgeons, scientists, clinical investigators, and medical advisors to develop the Barricaid solution for patients at high risk of recurrence following discectomy.

Following the company’s commitment to follow a responsible and evidence-based introduction of new technology, Barricaid has been rigorously studied through multiple trials, including a multicenter level I RCT demonstrating superior outcomes to discectomy alone leading to FDA Pre-Market Approval in 2019.

Intrinsic Therapeutics Code of Conduct

Barricaid is a patented technology.


If Barricaid is right for you, we can help.

Sign up to receive future updates and information on the Barricaid procedure.
  • This field is for validation purposes and should be left unchanged.